Serving leading biopharmaceutical companies globally:

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

BENLYSTA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Tradename: BENLYSTA

Patents:	42
Applicants:	2
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for BENLYSTA

Recent Clinical Trials for BENLYSTA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Rachel Jones	Phase 2
Medical Research Council	Phase 2
University of Cambridge	Phase 2

See all BENLYSTA clinical trials

Pharmacology for BENLYSTA

Mechanism of Action	B Lymphocyte Stimulator-directed Antibody Interactions
Physiological Effect	Decreased B Lymphocyte Activation

Patent Text Search: US Patents for BENLYSTA

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Human Genome Sciences Inc.	BENLYSTA	belimumab	INJECTABLE; INJECTION	125370	001	2011-03-09	Start Trial	The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)	2039-02-26	RX		search
Human Genome Sciences Inc.	BENLYSTA	belimumab	INJECTABLE; INJECTION	125370	001	2011-03-09	Start Trial	CureVac AG (Tubingen, DE)	2032-02-15	RX		search
Human Genome Sciences Inc.	BENLYSTA	belimumab	INJECTABLE; INJECTION	125370	001	2011-03-09	Start Trial	Exagen Diagnostics, Inc. (Vista, CA)	2031-02-11	RX		search
Human Genome Sciences Inc.	BENLYSTA	belimumab	INJECTABLE; INJECTION	125370	001	2011-03-09	Start Trial	ALX ONCOLOGY INC. (Burlingame, CA)	2035-08-07	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for BENLYSTA

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
China	103221072	Start Trial
China	101223448	Start Trial
European Patent Office	3204018	Start Trial
Japan	2015507925	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

McKesson

Baxter

McKinsey

Colorcon

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.